New drug Nesina for diabetes 2 listed on PBS

TIST-LOGO 3A new treatment option for up to 175,000 Australians living with type 2 diabetes (T2D), will be reimbursed on the Pharmaceutical Benefit
Scheme (PBS), according to a media release.

In an Australian-first, the availability of Nesina® (alogliptin) – a once-daily glucose
lowering tablet for T2DT2D – means T2D patients who are not well controlled on a single treatment will
be able to access reimbursement for this type of treatment earlier in the course of their diabetes.

Diabetes experts are welcoming the upcoming PBS listing of Nesina, which coincides with the
International Diabetes Federation (IDF) World Diabetes Congress, one of the world’s largest diabetes
conferences to be held in Melbourne next week.

According to Professor Stephen Colagiuri, Professor of Metabolic Health at the Institute of Obesity,
Nutrition and Exercise, University of Sydney, “The PBS listing of Nesina is good news for both
Australians with type 2 diabetes and their treating doctors.”

“The PBS listing of Nesina widens the access to this new treatment option for up to 175,0001,2
Australians living with type 2 diabetes who may be eligible for this treatment. However, doctors are
encouraged to consider the needs and preferences of each patient and provide individualised
treatment,” said Professor Colagiuri

The number of people with type 2 diabetes is increasing worldwide.5
In Australia, approximately 1.65
million people have type 2 diabetes6-7
which without intervention, is expected to rise to 2.31 million
Australians by 2035.

Sydney-based General Practitioner (GP) with a strong interest in diabetes, Dr John Barlow, says, “As
a progressive disease, people living with type 2 diabetes need to make challenging lifestyle changes
and many will need to take multiple treatments over time to help manage their disease.”

“When treating patients with type 2 diabetes, one size doesn’t fit all, and the addition of Nesina to the
PBS allows GPs to provide patients with an additional option in the management of their disease,” Dr
Barlow said.

Type 2 is the most common form of diabetes, affecting 85-90% of all people with diabetes. The
disease may occur at any age, however usually affects older adults, peaking between the ages of 65
and 74 years.9,10

According to Australian Diabetes Council (ADC) CEO, Nicola Stokes, “Diabetes is recognised as a
global health issue, and there are already over one million Australians living with the disease.”

“Proper care and management of all forms of diabetes is needed to ensure the onset of complications
can be prevented in those living with the disease. So, any new medication which can assist in this
outcome is a welcome addition to the diabetes arena.”

“By providing access to innovative and contemporary technologies and medications, the Australian
Government confirms its role as a partner in finding solutions to this critical health care issue,” said
Ms Stokes.

Share this :

About Ashok Kumar

Ashok Kumar is an accomplished journalist with over 38 years of experience in the profession in various capacities. He was a sub-editor in Patriot and later Chief Sub-editor in The Hindustan Times, New Delhi. He has several published articles and reports in Patriot and HT. Published reports in The Blacktown Sun in Sydney. He had also been a tutor in journalism in the University of Western Sydney. He is currently Editor at The Indian Sub-continent Times, Sydney.

View all posts by Ashok Kumar →

Leave a Reply